Drugs / MenABCWY+OMV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02451514 | Jun → Nov 2015 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenABCWY+OMV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02451514 ↗ |
| Known as | MenABCWY+Outer membrane Vesicles (OMV) | “The purpose of this study is to evaluate persistence of bactericidal antibodies for N. meningitidis serogroups A, C, W, and Y and serogroup B test strains approximately 4 years...” NCT02451514 ↗ |
| Modality | Vaccine | “MenABCWY+OMV vaccine” NCT02451514 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT02451514 ↗ |